Screener
Summit Therapeutics SMMT Total Revenue
Discontinued — last reported Q4 '24
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Summit Therapeutics’s 10-K, filed February 24, 2025.
- Filed
- Feb 24, 2025
- Fiscal year
- FY2024
- Accession
- 0001599298-25-000048
| Line item | Year Ended December 31, 2024 | Year Ended December 31, 2023 | Year Ended December 31, 2022 |
|---|---|---|---|
| Revenue | — | — | $705 |
| Operating expenses: | |||
| Research and development | 150,777 | 59,471 | 51,999 |
| Acquired in-process research and development | 15,007 | 520,915 | — |
| General and administrative | 60,527 | 30,265 | 26,743 |
| Impairment of intangible assets | — | — | 8,468 |
| Total operating expenses | 226,311 | 610,651 | 87,210 |
| Other operating income, net | 313 | 1,001 | 14,416 |
Item 16. Report Summary
FAQ
- What is Summit Therapeutics's total revenue?
- Summit Therapeutics (SMMT) reported total revenue of $0 in Q4 2024.
- What is the long-term trend for Summit Therapeutics's total revenue?
- Over 2 years (2021 to 2023), Summit Therapeutics's total revenue has grown at a -100.0% compound annual growth rate (CAGR), from $1.81M to $0.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Summit Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude